RBX2660 (microbiota suspension) for Recurrent C. difficile Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety Study

Mayur S. Ramesh, MD, Bharat Misra, MD, Henry Ford Hospital System, Detroit, MI; Arnab Ray, MD, Borland Groover Clinic, Jacksonville, FL; Robert Smith, MD, Ochsner Clinic, New Orleans, LA; Mary Kay Sobcinski, RN, MHA, Rebiotix Inc, Roseville, MN

RBX2660 (microbiota suspension) for Recurrent C. difficile Infection: 60-Day Interim Analysis of the PUNCH CD Phase 2 Safety Study

Download this poster (197 KB)
Download the abstract (31 KB)

Infectious Diseases Week 2014
October 8-12, 2014, Philadelphia, PA


The purpose of the PUNCH CD study was to assess the safety of RBX2660 (microbiota suspension) for recurrent infection (CDI). RBX2660 is a biologic drug consisting of a suspension of live human derived intestinal microbes. A secondary objective of the study was CDI resolution at 8 weeks.